| dc.contributor.author |
Mahesh, R. |
|
| dc.date.accessioned |
2023-11-23T05:47:12Z |
|
| dc.date.available |
2023-11-23T05:47:12Z |
|
| dc.date.issued |
2016 |
|
| dc.identifier.uri |
https://www.degruyter.com/document/doi/10.1515/jbcpp-2016-0057/html |
|
| dc.identifier.uri |
http://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13226 |
|
| dc.description.abstract |
Several preclinical studies have shown that serotonergic 5-HT3 receptor antagonists play an important role in the management of neuropsychiatric disorders, such as depression and anxiety. In the present study the compound “6n” (N-n-propyl-3-ethoxyquinoxaline-2-carboxamide), a novel 5-HT3 receptor antagonist with an optimal log P (2.52) and pA2 (7.6) value was screened for its neuro-pharmacological potential in chronic rodent models of depression and anxiety named traumatic brain injury (TBI). |
en_US |
| dc.language.iso |
en |
en_US |
| dc.publisher |
De Gruyter |
en_US |
| dc.subject |
Pharmacy |
en_US |
| dc.subject |
Neuropharmacological |
en_US |
| dc.subject |
Neurochemical |
en_US |
| dc.subject |
Traumatic brain injury (TBI) |
en_US |
| dc.title |
Neuropharmacological and neurochemical evaluation of N-n-propyl-3-ethoxyquinoxaline-2-carboxamide (6n): a novel serotonergic 5-HT3 receptor antagonist for co-morbid antidepressant- and anxiolytic-like potential using traumatic brain injury model in rats |
en_US |
| dc.type |
Article |
en_US |